-
Jan 2012
Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2.
European Journal of Clinical Pharmacology
E-Publication Ahead Of Print, 2012
View abstract and full text options
-
Dec 2011
Bottom-up modeling and simulation of tacrolimus clearance: prospective investigation of blood cell distribution, sex and CYP3A5 expression as covariates and assessment of study power.
Biopharmaceutics & Drug Disposition
32, 498-506, December 2011
View abstract and full text options
-
Dec 2011
Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance.
Clinical Pharmacokinetics
50, 809-822, December 2011
View abstract and full text options
-
Jul 2011
Are there differences in the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P4502C9? A systematic investigation into inter-system extrapolation factors.
Biopharmaceutics & Drug Disposition
32, 303-318, September 2011
View abstract and full text options
-
Jun 2011
Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover.
European Journal of Pharmaceutical Sciences
43, 160-173, June 2011
View abstract and full text options
-
Mar 2011
Modeling and predicting drug pharmacokinetics in patients with renal impairment.
Expert Reviews In Clinical Pharmacology
4, 261-274, March 2011
View abstract and full text options
-
Mar 2011
Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model.
Xenobiotica
41, 623-638, August 2011
View abstract and full text options
-
Mar 2011
Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice.
Pediatric Anesthesia
21, 291-301, March 2011
View abstract and full text options
-
Feb 2011
Physiologically-based pharmacokinetics in drug development and regulatory science.
Annual Reviews of Pharmacology & Toxicology
51, 45-73, February 2011
View abstract and full text options
-
Nov 2010
Determination of a quantitative relationship between hepatic CYP3A5*1/*3 and CYP3A4 expression for use in the prediction of metabolic clearance in virtual populations.
Biopharmaceutics & Drug Disposition
31, 516-532, November 2010
View abstract and full text options
-
Nov 2010
Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model.
Current Drug Metabolism
11, 716-729, November 2010
View abstract and full text options
-
Jun 2010
PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals.
Toxicology
106, 154-161, June 2010
View abstract and full text options
-
Mar 2010
Physiologically based mechanistic modelling to predict complex drug–drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on the time-course of exposure to triazolam.
European Journal of Pharmaceutical Sciences
39, 298-309, March 2010
View abstract and full text options
-
Mar 2010
A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance.
Clinical Pharmacokinetics
49, 189-206, March 2010
View abstract and full text options
-
Jul 2009
Assessing the efficiency of mixed effects modelling in quantifying metabolism based drug-drug interactions: using in vitro data as an aid to assess study power.
Pharmaceutical Statistics
8, 186-202, July-September 2009
View abstract and full text options
-
Jun 2009
Population-based mechanistic prediction of oral drug absorption.
The AAPS Journal
11, 225-237, June 2009
View abstract and full text options
-
May 2009
Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction.
Current Drug Metabolism
10, 420-432, May 2009
View abstract and full text options
-
Feb 2009
The Simcyp® population-based ADME simulator.
Expert Opinion on Drug Metabolism & Toxicology
5, 211-223, February 2009
View abstract and full text options
-
Jan 2009
Metabolism of dextrorphan by CYP2D6 in different recombinantly expressed systems and its implications for the in vitro assessment of dextromethorphan metabolism.
Journal of Pharmaceutical Sciences
98, 763-771, February 2009
View abstract and full text options
-
Jan 2009
A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of ‘Bottom-Up’ vs ‘Top-Down’ recognition of covariates.
Drug Metabolism & Pharmacokinetics
24, 53-75, 2009
View abstract and full text options
-
Dec 2008
Covariation of human microsomal protein per gram of liver with age: absence of influence of operator and sample storage may justify interlaboratory data pooling.
Drug Metabolism & Disposition
36, 2405-2409, December 2008
View abstract and full text options
-
Dec 2008
CYP2D6 is primarily responsible for the metabolism of clomiphene.
Drug Metabolism & Pharmacokinetics
23, 101-105, April 2008
View abstract and full text options
-
Jul 2008
The problems in scaling adult drug doses to children.
Archives of Disease in Childhood
93, 207-211, March 2008
View abstract and full text options
-
Jul 2008
Intestinal metabolism and transport of drugs in children: the effects of age
and disease.
Journal of Pediatric Gastroenterology & Nutrition
47, 3-10, July 2008
View abstract and full text options
-
Jun 2008
Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions.
Current Drug Metabolism
9, 384-394, June 2008
View abstract and full text options
-
May 2008
Development of CYP2D6 and CYP3A4 in the first year of life.
Clinical Pharmacology & Therapeutics
83, 670-671, May 2008
View abstract and full text options
-
Oct 2007
Disparity in holoprotein/apoprotein ratios of different standards
used for immunoquantification of hepatic cytochrome P450
enzymes.
Drug Metabolism & Disposition
35, 1733-1736, October 2007
View abstract and full text options
-
Oct 2007
Prediction of intestinal first-pass drug metabolism.
Current Drug Metabolism
8, 676-684, October 2007
View abstract and full text options
-
Jun 2007
Theoretical assessment of a new experimental protocol for determining kinetic values describing mechanism (time)-based enzyme inhibition.
European Journal of Pharmaceutical Sciences
31, 232-241, July 2007
View abstract and full text options
-
May 2007
Inactivation of CYP2D6 by methylenedioxymethamphetamine in different recombinant expression systems.
European Journal of Pharmaceutical Sciences
32, 8-16, September 2007
View abstract and full text options
-
Mar 2007
Misuse of the well-stirred model of hepatic drug clearance.
Drug Metabolism & Disposition
35, 501-502, March 2007
View abstract and full text options
-
Feb 2007
Kinetics of the time-dependent inactivation of CYP2D6 in cryopreserved human hepatocytes by methylenedioxymethamphetamine (MDMA).
European Journal of Pharmaceutical Sciences
31, 53-61, May 2007
View abstract and full text options
-
Jan 2007
The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies - CYP2C9 and warfarin as an example.
British Journal of Clinical Pharmacology
64, 14-26, July 2007
View abstract and full text options
-
Jan 2007
Simulation and prediction of in vivo metabolic drug clearance from in vitro data.
Nature Reviews Drug Discovery
6, 140-148, February 2007
View abstract and full text options
-
Jan 2007
Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver.
Current Drug Metabolism
8, 33-45, January 2007
View abstract and full text options
-
Jan 2007
Incorporating in vitro information on drug metabolism into clinical trial simulations to assess the effect of CYP2D6 polymorphisms on pharmacokinetics and pharmacodynamics: dextromethorphan as a model application.
Journal of Clinical Pharmacology
47, 175-186, February 2007
View abstract and full text options
-
Dec 2006
Prediction of plasma protein binding displacement and its implications for quantitative assessment of metabolic drug-drug interactions from in vitro data.
Journal of Pharmaceutical Sciences
95, 2778-2787, December 2006
View abstract and full text options
-
Nov 2006
Prediction of clearance of eleven drugs and associated variability in neonates, infants and children.
Clinical Pharmacokinetics
45, 931-956, September 2006
View abstract and full text options
-
Nov 2006
Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA.
Journal of Psychopharmacology
20, 842-849, November 2006
View abstract and full text options
-
Nov 2006
The impact of experimental design on assessing mechanism-based inactivation of CYP2D6 by MDMA (Ecstasy).
Journal of Psychopharmacology
20, 834-841, November 2006
View abstract and full text options
-
Jul 2006
Prediction of metabolic drug clearance in humans: in vitro-in vivo extrapolation vs allometric scaling.
Xenobiotica
36, 567-580, July 2006
View abstract and full text options
-
Jun 2006
Prediction of in vivo drug clearance from in vitro data.
I: Impact of inter-individual variability.
Xenobiotica
36, 473-497, June 2006
View abstract and full text options
-
Jun 2006
Prediction of in vivo drug clearance from in vitro data.
II: Potential inter-ethnic differences.
Xenobiotica
36, 499-513, June 2006
View abstract and full text options
-
Apr 2006
A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation.
Current Drug Metabolism
7, 315-334, April 2006
View abstract and full text options
-
Dec 2005
Changes in liver volume from birth to adulthood: a meta analysis.
Liver Transplantation
12, 1481-1493, December 2005
View abstract and full text options
-
Nov 2005
Kinetic values for mechanism-based enzyme inhibition: assessing the bias introduced by the conventional experimental protocol.
European Journal of Pharmaceutical Sciences
26, 334-340, November 2005
View abstract and full text options
-
Jun 2005
Modelling approaches to dose estimation in children.
British Journal of Clinical Pharmacology
59, 663-669, June 2005
View abstract and full text options
-
Dec 2004
Prediction of drug clearance from in vitro data for 10 drugs in neonates, infants and children using Simcyp.
Drug Metabolism Reviews
36, Supplement 1, A680, 340, December 2004
-
Dec 2004
Predicting the clearance of CYP2C9 substrates.
Drug Metabolism & Disposition
32, 1522-1523, December 2004
View abstract and full text options
-
Dec 2004
In silico simulations to assess the in vivo consequences of in vitro metabolic drug-drug interactions.
Drug Discovery Today: Technologies
1, 441-448, December 2004
View abstract and full text options
-
Dec 2004
Assessment of in vivo CYP2D6 activity: differential sensitivity of commonly used probes to urine pH.
Journal of Clinical Pharmacology
44, 1398-1404, December 2004
View abstract and full text options
-
Oct 2004
Cytochrome P450 3A expression and activity in the human small intestine.
Clinical Pharmacology & Therapeutics
76, 391, October 2004
View abstract and full text options
-
Oct 2004
Predicting drug-drug interactions: in vitro veritas?
EUFEPS 2004 - 8th European Congress of Pharmaceutical Sciences
October 17th-20th 2004, Brussels, Belgium.
Abstract published in:
European Journal of Pharmaceutical Sciences
23, SS5-3, 13, October 2004
View abstract and full text options
-
Jul 2004
Pharmacogenetics - expectations and reality.
British Medical Journal
329, 4-6, July 2004
View abstract and full text options
-
May 2004
Prediction of drug clearance and its variability in neonates, infants and
children using Simcyp.
European Society for Developmental, Perinatal and Paediatric
Pharmacology, 9th Congress
June 16th-19th 2004, Marburg, Germany.
Abstract published in:
Paediatric and Perinatal Drug Therapy
6, L23, 51, May 2004
View abstract and full text options
-
May 2004
A comparison of methods to predict drug clearance in neonates,
infants and children.
Proceedings of the British Pharmacological Society
December 16th-18th 2003, GKT School of Biomedical Sciences,
King’s College London, Guy’s Campus.
Abstract published in:
British Journal of Clinical Pharmacology
57, A23, 677-678, May 2004
View abstract and full text options
-
Feb 2004
Prediction of clearance from recombinantly expressed CYPs: Intersystem extrapolation factor (ISEF).
Xenobiotica
34, 151-178, February 2004
View abstract and full text options
-
Dec 2003
Abundance of cytochromes P450 in human liver: a meta-analysis.
British Pharmacological Society Winter Meeting
University of London, December 2003
View abstract and full text options
-
Dec 2003
Reference values for the amount of microsomal protein and number of hepatocytes per gram of human liver.
Drug Metabolism Reviews
35, Supplement 1, A200, 100, April 2003
View abstract and full text options
-
Dec 2003
Sources of variability associated with quantitative predictions of drug clearance from recombinant CYP enzymes.
Drug Metabolism Reviews
35, Supplement 1, A202, 101, April 2003
View abstract and full text options
-
Oct 2003
The effects of dose staggering on metabolic drug-drug interactions.
European Journal of Pharmaceutical Sciences
20, 223-232, October 2003
View abstract and full text options
-
Oct 2003
Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver.
British Journal of Clinical Pharmacology
56, 433-440, October 2003
View abstract and full text options
-
Jul 2003
Physiologically based modelling of inhibition of metabolism to assess the relative potency of drug and metabolite: dextromethorphan vs dextrorphan using quinidine Inhibition.
British Journal of Clinical Pharmacology
56, 57-67, July 2003
View abstract and full text options
-
Apr 2003
ISEF: an intersystem extrapolation factor for use with recombinant cytochrome P450 expressed systems.
Proceedings of the British Pharmacological Society
January 7th-10th 2003, William Harvey Research Institute, Bart’s and the London, Queen Mary’s School of Medicine and Dentistry.
Abstract published in:
British Journal of Clinical Pharmacology
55, A35, 437-438, April 2003
View abstract and full text options
-
Apr 2003
Determining values for human microsomal protein per gram of liver.
Proceedings of the British Pharmacological Society
January 7th-10th 2003, William Harvey Research Institute, Bart’s and the London, Queen Mary’s School of Medicine and Dentistry.
Abstract published in:
British Journal of Clinical Pharmacology
55, A2, 418-419, April 2003
View abstract and full text options
-
Apr 2003
Prediction of age related changes in midazolam clearance in children
using SIMCYP.
Proceedings of the British Pharmacological Society
January 7th-10th 2003, William Harvey Research Institute, Bart’s and the London, Queen Mary’s School of Medicine and Dentistry.
Abstract published in:
British Journal of Clinical Pharmacology
55, A26, 432-433, April 2003
View abstract and full text options
-
Apr 2003
In vitro prediction of population in vivo drug clearance using updated
scaling factors.
Proceedings of the British Pharmacological Society
January 7th-10th 2003, William Harvey Research Institute, Bart’s and the London, Queen Mary’s School of Medicine and Dentistry.
Abstract published in:
British Journal of Clinical Pharmacology
55, A49, 445, April 2003
View abstract and full text options
-
Dec 1999
Acute inhibition of methadone metabolism by ritonavir: projection of interaindividual variability from in vitro data.
Proceedings of the British Pharmaceutical Society
July 14th-16th 1999, University of Nottingham.
Abstract published in:
British Journal of Clinical Pharmacology
48, A16, 883-884, 1999
-
Jun 1999
In vivo indices of enzyme activity-the effect of renal impairment on the assessment of CYP2D6 activity.
Pharmacogenetics
9, 277-286, June 1999
View abstract and full text options
-
Jun 1999
In vivo indices of enzyme activity-the effect of renal impairment on the assessment of CYP2D6 activity.
Proceedings of the British Pharmaceutical Society
January 6th-8th 1999, Stakis Metropole Hotel, Brighton (King's College London).
Abstract published in:
British Journal of Clinical Pharmacology
47, A4, 577-578, 1999
-
Dec 1998
The determination of drug metabolising enzyme activity in vivo: pharmacokinetics and statistical issues.
Xenobiotica
28, 1255-1273, December 1998
View abstract and full text options
-
Dec 1996
Caffeine metabolic ratios as markers of enzyme activity: a theoretical assessment.
Pharmacogenetics
6, 121-49, April 1996
View abstract and full text options